Add to Calendar 3/27/2019 8:15:00 AM 3/28/2019 2:30:00 PM 2019 Annual Meeting: State of Possible Conference
This year’s Annual Meeting is now the State of Possible Conference where we'll celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks, inspiring and engaging content in the style of a TED Talk. We'll also have a networking reception, the State of Possible Celebration, immediately following Day 1 of the conference, where we'll have great food, drinks, a DJ. Attendees will also have access to the exhibits at the Museum of Science. Join us as we celebrate the State of Possible!
 

If you haven’t attended our Annual Meeting before, it is the premier east coast life sciences conference and this year’s event is better than ever. With speakers like Katrine Bosley, John Maraganore, Jeremy Levin, George Church, and more, we have some of the brightest names in biotech talking about the issues impacting our industry. See our incredible lineup of speakers and topics below. Online registration closes at noon on Tuesday, March 26th. Walk-in registrations will be available on-site. 

 Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
CEO, X4 Pharmaceuticals
Dr. Ragan is a founder, as well as the Chief Executive Officer and President of X4. She has more than 19 years of experience building companies in the biotechnology industry. Most recently, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc (LTI), an Atlas Venture portfolio company, where she led the company’s business development activities. Prior to LTI, Dr. Ragan held leadership roles in corporate development and operations at Genzyme/Sanofi where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her BS in Mechanical Engineering from Tufts University and her PhD from MIT. She completed post-doctoral studies at Harvard Medical School.

Brought to you by